European funding for the treatment of Type 1 diabetes using 3D bioprinting

IBEC researcher Javier Ramón Azcón has been awarded an “ERC Proof of Concept Grant.” This prestigious funding is granted by the European Research Council to explore the commercial and societal potential of research projects conducted in European institutions. Ramón’s project, Uniink, is centered on the treatment of Type 1 diabetes using cell therapy and 3D bioprinting.

Innovative bioengineered spheres might help treating diabetes

Researchers from IBEC, in collaboration with IDIBAPS in Barcelona, have developed nontoxic small spheres able to respond to variations in glucose levels, and producing insulin in vitro. These biomimetic spheroids containing pancreatic β-cells were prepared based on 3D bioprinting. This approach might help in the future improving clinical outcomes of β-cell transplantation strategies for diabetes treatment, as well as for in vitro drug screening platforms.

14th IBEC Symposium brings international experts and 300 attendees together

International experts and three hundred registered attendees met in the 14th IBEC Symposium, dedicated to regenerative therapies. Organised by the Institute for Bioengineering of Catalonia (IBEC), speakers presented the latest advances in mini-organs, organs on a chip, 3D bioprinting and tissue engineering, among others.

New biosensor detects inflammatory marker in muscle with high sensitivity

In a recent publication in the journal Nanophotonics, IBEC researchers present a new biosensor for the direct and sensitive detection of the protein interleukin-6 in muscle, an indicator of inflammation and potential disease, proving the high performance of the device on bioengineered 3D skeletal muscles. This new approach may result in a promising tool for measuring the efficacy of drug candidates for diseases where inflammation is present such as muscular dystrophy.

Towards a treatment for myotonic dystrophy: the first 3D model with patient cells

IBEC researchers led by Javier Ramón and Juan M. Fernández develop the first three-dimensional model for myotonic dystrophy, a rare disease that currently has no cure. The model combines patient cells and bioengineering techniques and represents a major advance over the use of animals and cell cultures. This new model will help in the design of personalized and more effective treatments, and for drug testing in a much more efficient way.